Home
禄 City specials
禄 Hangzhou
Hangzhou grants fund for drug innovation
Print Edition
Hangzhou government has awarded up to 30 million yuan (US$4.6 million) for the development and research of first-class innovative medicines and up to 12 million yuan for the upgrading of such treatments.
The grants are in line with the State Council鈥檚 14th Five-Year Plan (2021-25) which boosts biopharmaceutical science and targets the building of a group of national bio-pharmaceutical laboratories across the country.
Hangzhou is encouraging more companies to cooperate with local hospitals in clinical trials and study through CRO (contract research organization), CMO (contract manufacture organization), and CDMO (contract development manufacture organization).
If a product is granted the National Registration Certificate for Medical Device for the first time, local departments will subsidize it up to 6 million yuan according to its original R&D expenditure.
If the fixed-asset investment of a pharmaceutical project surpasses 200 million yuan, Hangzhou will subsidize up to 20 percent of the total investment, aiming to accelerate the speed of commercialization.
Software companies building online platforms for medical registration, intellectual property trade and pubic medical services are also included in the new policy.
If evaluated by government as a key platform, the company will be granted up to 18 million yuan. Others will be awarded up to 1 million yuan.
With the pharmaceutical industry highly dependent on policies, Hangzhou hopes to become one of the sector鈥檚 hubs in China by launching attractive subsidies.
In recent years, companies with a capacity to develop original drugs have been emerging in the city.
Betta Pharmaceuticals, a listed company founded by several PhD graduates who returned from the US, produced and developed China鈥檚 first home-grown anti-cancer targeted drug. The medicine received a patent in 2007 and was launched on the market as Conmana in 2011.
During the first half of 2020, Conmana led the Chinese market with cumulative sales reaching 924 million yuan, benefiting more than 250,000 lung cancer patients.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
